Metabolic
Stories
-
Semaglutide 2.4 mg scored 7.3 points above placebo on KCCQ-CSS in HFpEF with type 2 diabetes
In a 617-participant trial, the KCCQ-CSS difference between semaglutide 2.4 mg and placebo was 7.3 points at week 52, the Novo Nordisk record shows. The record now holds results for a completed trial in obesity-related heart failure with preserved ejection fraction and type 2 diabetes.